Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

The MHRA has strengthened addiction warnings for Z-drugs, benzodiazepines, and gabapentinoids after a review found risks of ...

44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

A new study suggests that common medications prescribed to help manage ADHD, such as Adderall and Ritalin, may work ...

Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma industry by market cap. | Two investigational cardiometabolic drugs from Eli ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Dr Emma Svennberg, cardiologist in Stockholm and first author of the consensus paper, noted that modern AF care requires a more streamlined and holistic approach. She highlighted the need to address ...